






SELECT NON-INSULIN TREATMENTS FOR TYPE 2 DIABETES*

JANUMET® and JANUMET® XR Product Monograph, Merck Canada Inc., December 18, 2019. **18.** KAZANO® Product Monograph, Takeda Canada Inc., March 16, 2020. **19.** KOMBOGLYZE® Product Monograph, AstraZeneca Canada Inc., March 20, 2018. **20.** DIAβETA® Product Monograph, sanofi-aventis Canada Inc., November 23, 2016. **21.** DIAMICRON® Product Monograph, SERVIER CANADA Inc., September 13, 2019. **22.** DIAMICRON® MR Product Monograph, SERVIER CANADA Inc., September 12, 2019. **23.** EUGLUCON® Product Monograph, Pharmascience Inc., May 2, 2011. **24.** GlucoNorm® Product Monograph, Novo Nordisk Canada Inc., September 9, 2015. **25.** ADLYXINE™ Product Monograph, sanofi-aventis Canada Inc., May 23, 2017. **26.** BYDUREON® Product Monograph, AstraZeneca Canada Inc., December 18, 2019. **27.** BYETTA® Product Monograph, AstraZeneca Canada Inc., December 18, 2019. **28.** OZEMPIC® Product Monograph, Novo Nordisk Canada Inc., July 31, 2020. **29.** RYBELSUS® Product Monograph, Novo Nordisk Canada Inc., March 20, 2020. **30.** TRULICITY® Product Monograph, Eli Lilly Canada Inc., August 15, 2019. **31.** Victoza® Product Monograph, Novo Nordisk Canada Inc., February 26, 2020. **32.** GLUCOBAY™ Product Monograph, Bayer Inc., June 10, 2010. **33.** AVANDIA® Product Monograph, GlaxoSmithKline Inc., October 4, 2017.











* Data from separate Product Monographs. Comparative clinical significance unknown. Please refer to the respective Product Monographs for complete information.












BIGUANIDE¹

GLUCOPHAGE^{®2} metformin hydrochloride tablets) Sanofi-aventis Canada Inc.	 500 mg	 850 mg
GLUMETZA^{®3} metformin hydrochloride extended-release tablets, (Mfr. Std.) Valeant Canada LP	 500 mg	 1000 mg
GLUMETZA[®] (SB)³ metformin hydrochloride extended-release tablets, (Mfr. Std.) Valeant Canada LP	 1000 mg	










SGLT2 INHIBITORS¹

JARDIANCE^{®4} empagliflozin tablets) Boehringer Ingelheim (Canada) Ltd.	 10 mg	 25 mg
FORXIGA^{®5} dapagliflozin tablets) AstraZeneca Canada Inc.	 5 mg	 10 mg
INVOKANA^{®6} canagliflozin tablets) Janssen Inc.	 100 mg	 300 mg
STEGLATRO^{™7} ertugliflozin tablets) Merck Canada Inc.	 5 mg	 15 mg

SGLT2 INHIBITORS + METFORMIN^{1,8-11}

Pr SYNJARDY^{®8} (empagliflozin and metformin hydrochloride tablets) Boehringer Ingelheim (Canada) Ltd.	 5 mg/500 mg	 5 mg/850 mg	 5 mg/1000 mg
Pr INVOKAMET^{®9} (canagliflozin and metformin hydrochloride tablets) Janssen Inc.	 12.5 mg/500 mg	 12.5 mg/850 mg	 12.5 mg/1000 mg
	 50 mg/500 mg	Image currently unavailable 50 mg/850 mg	 50 mg/1000 mg
Pr INVOKAMET XR^{™10} (canagliflozin and metformin hydrochloride extended-release tablets) Janssen Inc.	Image currently unavailable 50 mg/500 mg	Image currently unavailable 50 mg/1000 mg	
	Image currently unavailable 150 mg/500 mg	Image currently unavailable 150 mg/1000 mg	
Pr XIGDUO^{®11} (dapagliflozin and metformin hydrochloride tablets) AstraZeneca Canada Inc.	 5 mg/850 mg	 5 mg/1000 mg	 5 mg/1000 mg

DPP-4 INHIBITORS¹

Pr TRAJENTA^{®12} (linagliptin tablets) Boehringer Ingelheim (Canada) Ltd.	 5 mg		
Pr JANUVIA^{®13} (sitagliptin tablets) Merck Canada Inc.	 25 mg	 50 mg	 100 mg
Pr NESINA^{®14} (alogliptin tablets) Takeda Canada Inc.	 6.25 mg	 12.5 mg	 25 mg
Pr ONGLYZA^{®15} (saxagliptin tablets) AstraZeneca Canada Inc.	 2.5 mg	 5 mg	

Data from separate Product Monographs. Comparative clinical significance unknown. Please refer to the respective Product Monographs for complete information.

SGLT2=sodium-glucose cotransporter-2; DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide 1.








DPP-4 INHIBITORS + METFORMIN^{1,16-19}

Pr JENTADUETO ^{®16} (linagliptin/metformin hydrochloride tablets) Boehringer Ingelheim (Canada) Ltd.	 2.5 mg/500 mg	 2.5 mg/850 mg	 2.5 mg/1000 mg
Pr JANUMET ^{®17} (sitagliptin and metformin hydrochloride tablets) Merck Canada Inc.	 50 mg/500 mg	 50 mg/850 mg	 50 mg/1000 mg
Pr JANUMET XR ^{®17} (sitagliptin and metformin hydrochloride modified-release tablets) Merck Canada Inc.	 50 mg/500 mg	 50 mg/1000 mg	 100 mg/1000 mg
Pr KAZANO ^{®18} (alogliptin and metformin hydrochloride tablets) TAKEDA Canada Inc.	 12.5 mg/500 mg	Image currently unavailable 12.5 mg/850 mg	 12.5 mg/1000 mg
Pr KOMBOGLYZE ^{®19} (saxagliptin and metformin hydrochloride tablets) AstraZeneca Canada Inc.	 2.5 mg/500 mg	 2.5 mg/850 mg	 2.5 mg/1000 mg






INSULIN SECRETAGOGUE' Sulfonylureas

Pr DIABETA ^{®20} (glyburide tablets) sanofi-aventis Canada Inc.	 2.5 mg	 5 mg
Pr DIAMICRON ^{®21} (gliclazide tablets) SERVIER CANADA Inc.	 80 mg	
Pr DIAMICRON MR ^{®22} (gliclazide tablets) SERVIER CANADA Inc.	 30 mg	 60 mg
Pr EUGLUCON ^{®23} (glyburide tablets) Pharmascience Inc.	Image currently unavailable 5 mg	



INSULIN SECRETAGOGUE' Meglitinides

Pr GlucosNorm ^{®24} (repaglinide tablets) Novo Nordisk Canada Inc.	 0.5 mg	 1 mg	 2 mg
--	---	---	---



GLP-1 RECEPTOR AGONISTS'

Pr ADLYXINE ^{™25} (lixisenatide injection) sanofi-aventis Canada Inc.	 0.05 mg/mL prefilled pen	 0.1 mg/mL prefilled pen	
Pr BYDUREON ^{®26} (exenatide for extended-release injectable suspension) AstraZeneca Canada Inc.	 2 mg/dose prefilled pen		
Pr BYETTA ^{®27} (exenatide injection) AstraZeneca Canada Inc.	 1.2 mL prefilled pen	 2.4 mL prefilled pen	
Pr OZEMPIC ^{®28} (semaglutide injection) Novo Nordisk Canada Inc.	 2 mg/pen (1.34 mg/mL) prefilled pen (delivers doses of 0.25 mg or 0.5 mg)	 4 mg/pen (1.34 mg/mL) prefilled pen (delivers doses of 1 mg)	
Pr RYBELSUS ^{®29} (semaglutide tablets) Novo Nordisk Canada Inc.	Image currently unavailable 3 mg	Image currently unavailable 7 mg	Image currently unavailable 14 mg
Pr TRULICITY ^{®30} (dulaglutide injection) Eli Lilly Canada Inc.	 0.75 mg/0.5 mL prefilled pen	 1.5 mg/0.5 mL prefilled pen	
Pr VICTOZA ^{®31} (liraglutide injection) Novo Nordisk Canada Inc.	 3 mL prefilled pen		






ALPHA-GLUCOSIDASE INHIBITOR'

Pr GLUCOBAY ^{™32} (acarbose tablets) Bayer Inc.	 50 mg	 100 mg
---	--	---



THIAZOLIDINEDIONE (TZD)'

Pr AVANDIA ^{®33} (rosiglitazone tablets) GlaxoSmithKline Inc.	 2 mg	 4 mg	 8 mg
---	---	---	---

Tablets shown are not actual size.

JARDIANCE®, JENTADUETO®, SYNJARDY® and TRAJENTA® are registered trademarks of Boehringer Ingelheim International GmbH, used under license.

TRULICITY® is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates.


All other trademark(s) are the property of their respective owners.

References: **1.** Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. *Can J Diabetes* 2018;42(Suppl 1):S1-S325. **2.** GLUCOPHAGE® Product Monograph, sanofi-aventis Canada Inc., March 2, 2018. **3.** GLUMETZA® and GLUMETZA (SB) Product Monograph, Valeant Canada LP, June 14, 2012. **4.** JARDIANCE® Product Monograph, Boehringer Ingelheim (Canada) Ltd., April 15, 2020. **5.** FORXIGA® Product Monograph, AstraZeneca Canada Inc., June 29, 2020. **6.** INVOKANA® Product Monograph, Janssen Inc., May 20, 2020. **7.** STEGLATRO™ Product Monograph, Merck Canada Inc., May 8, 2018. **8.** SYNJARDY® Product Monograph, Boehringer Ingelheim (Canada) Ltd., April 28, 2020. **9.** INVOKAMET® Product Monograph, Janssen Inc., August 18, 2020. **10.** INVOKAMET XR™ Product Monograph, Janssen Inc., May 21, 2020. **11.** XIGDUO® Product Monograph, AstraZeneca Canada Inc., April 21, 2020. **12.** TRAJENTA® Product Monograph, Boehringer Ingelheim (Canada) Ltd., May 19, 2020. **13.** JANUVIA® Product Monograph, Merck Canada Inc., November 1, 2018. **14.** NESINA® Product Monograph, Takeda Canada Inc., October 24, 2018. **15.** ONGLYZA® Product Monograph, AstraZeneca Canada Inc., December 12, 2018. **16.** JENTADUETO® Product Monograph, Boehringer Ingelheim (Canada) Ltd., June 12, 2020.

MEMBER OF
INNOVATIVE MEDICINES CANADA

PAAB

EMP-CA-101089A
EMP-LI-101089A

 **Boehringer
Ingelheim**

Lilly